WO2003002101A1 - Oral pharmaceutical compositions with improved bioavailability - Google Patents

Oral pharmaceutical compositions with improved bioavailability Download PDF

Info

Publication number
WO2003002101A1
WO2003002101A1 PCT/EP2002/006748 EP0206748W WO03002101A1 WO 2003002101 A1 WO2003002101 A1 WO 2003002101A1 EP 0206748 W EP0206748 W EP 0206748W WO 03002101 A1 WO03002101 A1 WO 03002101A1
Authority
WO
WIPO (PCT)
Prior art keywords
amphiphilic
cyclodextrins
active ingredient
composition
superdisintegrants
Prior art date
Application number
PCT/EP2002/006748
Other languages
French (fr)
Inventor
Maria Gabriella Massironi
Original Assignee
Farmatron Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Farmatron Ltd. filed Critical Farmatron Ltd.
Priority to DE60205905T priority Critical patent/DE60205905T2/en
Priority to AU2002321081A priority patent/AU2002321081B2/en
Priority to AT02754706T priority patent/ATE303137T1/en
Priority to CA2451377A priority patent/CA2451377C/en
Priority to EP02754706A priority patent/EP1401405B1/en
Priority to JP2003508340A priority patent/JP4509552B2/en
Priority to US10/482,460 priority patent/US7867517B2/en
Publication of WO2003002101A1 publication Critical patent/WO2003002101A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds

Definitions

  • the present invention relates to prompt-release oral pharmaceutical compositions containing one or more active principles solubilised, suspended or embedded in an amphiphilic matrix which is suitably formulated to increase in vitro and in vivo the bioavailability of medicaments sparingly absorbed through the oral route and/or with problems of high variability of absorption in the gastrointestinal tract.
  • Formulation of drugs in amphiphilic matrix systems, with other surfactants, superdisintegrants and other excipients which are used for obtaining pharmaceutical forms having suitable technological properties allows to increase the in vitro dissolution rate, to improve bioavailability and to have less absorption variability.
  • the prompt-release compositions of the invention can contain active principles belonging to the therapeutical classes of analgesic, anti- inflammatory, antineoplastic, immunomodulating, antihemetic, antidiabetic, cardiovascular, hypnotic, tranquilizing, antihistamine drugs, antibiotics, antidepressant.
  • Prompt-release, fast- absorption and improved bioavailable formulations can be prepared according to different known techniques: Complexes and composites based on cyclodextrins or other polymers, in which the active ingredient has been loaded through solubilisation in water or other organic solvents, co-grinding to dryness or in organic solvents and/or freeze-drying.
  • Micronisation and amorphisation processes of the active ingredient Emulsions, microemulsions (W/O, O/W), multiple emulsions ( /O/W). Salification processes, even extemporary, or solubilization of the active ingredient as such or in conventional liquid formulations such as syrups, drops, solutions, soft-gelatin capsules, effervescent forms.
  • Organic solvents and/or cosolvents such as dioxane, dimethylacetamide, dimethylsulfoxide, dimethyl isosorbide or binary or multiple systems consisting of diethylene glycol monoethyl ether with polyethylene glycols added with non-ionic surfactants.
  • Micronisation processes do not always ensure significant increases in plasma levels, while increasing the apparent density / volumes and surface areas of the powders thus making the production of capsules, tablets and granulates troublesome.
  • Amorphisation processes although improving the bioavailability of the drugs, induce recrystallization in the time and often also lower stability of the active ingredient, thus negatively affecting the quality of the medicament.
  • Emulsions and/or microemulsions are often unstable and cannot carry pharmacologically active amounts of the medicament.
  • Salification and/or solubilization processes of conventional pharmaceutical forms sometime cannot improve the bioavailability of sparingly permeable and absorbable, or lipophilic, medicaments, due to reprecipitation of the active ingredient in the biological fluids, thus removing the advantage of a technological process aiming at dissolving the medicament in the pharmaceutical formulation.
  • Prompt-release, improved bioavailability formulations should ensure the standardization of the physical pharmaceutical state of the active ingredient, for fast release from the pharmaceutical form and to reduce any deviation from linear release.
  • compositions of the invention are characterized by a fast onset phase of the amount of drug which under sink conditions remains rapid until complete solubilization, dispersion and/or extemporaneous and/or in situ emulsification of the system, which quickly releases the active ingredient in the gastrointestinal tract.
  • the prompt-release oral pharmaceutical compositions present invention comprise: 1. a matrix consisting of amphiphilic compounds either liquid or with melting point below 60°C, possibly to form eutectic mixture melting at 35-37°C, in which the active ingredient is at least partially soluble and/or dispersed and/or embedded or granulated with amphiphilic compound previously solubilised or suspended in solvent (preferably water);
  • a surface acting component which is compatible with the amphiphilic matrix and can be homogeneously solubilized and/or dispersed therein;
  • compositions of the invention can be obtained with a process which comprises the following steps: a) adding surfactants to the amphiphilic matrix, to obtain a homogeneous solution or dispersion; b) solubilizing, suspending, dispersing, totally or partly embedding one or more active principles; c) adding cyclodextrins and/or superdisintegrants, or granulating or dispersing with cyclodextrins and/or polymers; d) optionally adding excipients; e) optionally film-coating with cellulose derivatives or methacrylic acid polymers.
  • step a) the surface-activated amphiphilic matrix is prepared.
  • any amphiphilic semisolid excipients or mixtures thereof are melted above 60°C, or solubilised or suspended in solvent (preferably water) to obtain a homogeneous solution and/or dispersion, which becomes again semisolid or solid at room temperature, with eutectic properties at temperatures ranging from 35°C to 37°C (body temperature) or able to be used as granulating system.
  • solvent preferably water
  • step b) the active ingredient is solubilised, dispersed and/or embedded in the surface-activated amphiphilic matrix from step a) to obtain a homogeneous solution and/or dispersion and/or granules.
  • step c) the system from step (b) is added with different amounts of cyclodextrins and/or superdisintegrants until homogeneous dispersion.
  • the resulting system can be distributed into soft- or hard- gelatin capsules to obtain a liquid, semisolid or solid pharmaceutical form inside the capsule.
  • the system from step (b) can be loaded onto cyclodextrins and/or superdisintegrants and/or mixtures thereof to obtain powder, microgranules or granules having good free-flowing and/or tabletting characteristics.
  • excipients with different functions may be added to transform liquid or semisolid formulations into solid ones for the preparation of capsules, tablets, granulates, microgranules, minitablets, sachets, said excipients being, for example, silica, celluloses, starches, sugars, polyvinyl pyrrolidones, methacrylates, glidants, antiaggregants, lubricants such as magnesium stearate, stearic acid, talc, or the liquid semisolid formulations can be added with other liquid cosolubilizers, such as, water, polyethylene glycols, glycerin, sorbitol.
  • adjuvants can be selected from preservatives (parabens, benzalkonium chloride), mineral and organic acid /bases, antioxidiizers (BHT, BHA, tocopherols), stabilizers (EDTA).
  • preservatives parabens, benzalkonium chloride
  • mineral and organic acid /bases mineral and organic acid /bases
  • antioxidiizers BHT, BHA, tocopherols
  • EDTA stabilizers
  • Amphiphilic compounds for use in the present invention comprise polar lipids (lecithin, phosphatidyl choline, phosphatidyl diethanolamine), ceramides, glycol alkyl ethers such as diethylene glycol monoethyl ether
  • Transcutol macrogolglycerids consisting of mixtures of mono- di- and triglycerids and polyethylene glycols and fatty acids (gelucire 44/14; gelucire 50/13) mono and diesters, polyethylene glycols hydroxystearates (Solutol ® HS 15).
  • Surfactants for use for use in the present invention comprise phosphatides and lecithins (phosphatidyl cholines, phosphatidyl diethanolamines, sphyngomyelins), anionic and non-ionic emulsifying waxes, sodium lauryl sulfate, sodium dodecyl sulfate, polysorbates, cholic acids, poloxamer, sodium sulfosuccinate, sodium lauryl sarcosinate.
  • phosphatides and lecithins phosphatidyl cholines, phosphatidyl diethanolamines, sphyngomyelins
  • anionic and non-ionic emulsifying waxes sodium lauryl sulfate, sodium dodecyl sulfate, polysorbates, cholic acids, poloxamer, sodium sulfosuccinate, sodium lauryl sarcosinate.
  • Cyclodextrins and superdisintegrants for use in the present invention comprise alpha-beta-gamma cyclodextrins, hydroxyethylcyclodextrins, methylcyclodextrins, hydroxypropylcyclodextrins, sodium starch glycolate (Explotab®), croscarmellose sodium (Acdisol ), cross-linked polyvinylpyrrolidone, Amberlites (IRP 88).
  • an amphiphilic matrix is first is prepared, which is added with one or more surfactants in amounts that usually do not exceed 10% w/w, preferably in amounts from 0.1% to 5%.
  • This mixture may be added with amounts of cyclodextrin or superdisintegrant of up to 10%, preferably from 0.1% to 2.5%, to obtain a homogeneous dispersion.
  • the active ingredient may be dissolved and/or dispersed in this system up to concentrations ranging from 0.1% to 50%, preferably from 0.1% to 4.9%.
  • the resulting formulation may be used for filling into hard- or soft- gelatin capsules.
  • the liquid or semisolid amphiphilic matrix may be used as granulating component. Once melted, or solubilised/suspended in solvents (preferably water), this matrix containing part of the surfactants, dextrins, superdisintegrants and active ingredient solubilised or dispersed, can be added to a significant amount of superdisintegrants and/or cyclodextrins already containing the remainder of the active ingredient, to obtain a solid composition ready for filling into capsules or sachets, or for transformation into tablets with the addition of suitable adjuvants such as silica, microcrystalline celluloses, starches, lubricants.
  • solvents preferably water
  • the semisolid amphiphilic matrix is cooled and subjected to extrusion and/or granulation, to make the formulation compact until obtaining an easy-to-process granule or microgranule.
  • the final pharmaceutical form may be prepared by dry- or wet- granulation.
  • the capsules, microgranules and/or tablets can be subjected to conventional coating processes with gastro-soluble films or gastro-protected with cellulose and methacrylic polymers.
  • the active principles which can be conveniently formulated according to the invention comprise:
  • Antineoplastics and immunomodulators such as: cyclophosphamide, chlorambucil, melfalan, busulfan, methotrexate, fludarabine, mercaptopurine, thioguanine, fluorouracil, tegafur, etoposide, idarubicin, procarbazine, estramustine, hydroxy carbamide, irinotecan, topotecan, tretinoin, medroxyprogesterone, megestrol, tamoxifen, toremifen, bicalutamide, flutamide, aminoglutetimide, anastrozole, exemestane, letrozole, levamisole, cyclosporin, micofenolate mofetil, tacrolimus, doxorubicin, epirubicin, dacarbazine, paclitaxel, daunorubicin, , irinotecan and camptotecins. 2.
  • Anti-inflammatories, analgesics and antirheumatics such as: acetaminophen, phenacetin, sodium salicylate, acetametacin, diclofenac, fentiazac, indomethacin, proglumetacin, sulindac, cinnoxicam, meloxicam, piroxicam, tenoxicam, thiaprophenic acid, flurbiprofene, furprofene, ibuprofen, ketoprofen, naproxen, oxaprozin, mefenamic acid, niflumic acid, amtolmetin guacil, nabumetone, nimesulide, etodoloac, celecoxib, glucosamine and its salts.
  • analgesics and antirheumatics such as: acetaminophen, phenacetin, sodium salicylate, acetametacin
  • Anti-inflammatories such as: olsalazine, 5- aminosalicylic, sulfasalazine, budesonide, ciclesonide,betamethasone, beclomethasone, fhmisolide, triamcinolone, mometasone.
  • Drugs for the treatment of bone diseases such as: alendronic acid, clodronic acid, etidronic acid, risedronate, tiludronate.
  • Prostatic such as: tamsulosin.
  • Anti-acne tretinoin, isotretinoin.
  • Antivirals such as: acyclovir, amprenavir, saquinavir, ritonavir.
  • Hormons and peptides growth hormons, insuline, calcitonin, gosereline, leuprolide, buserelin, , follitropin.
  • Ematological such as : erithropoyetin, bromeline.
  • Antitussives such as: dextromethorphan, codeine phosphate, levodropropizine.
  • Systemic antihistamines such as: mequitazine, prometazine, cetrizine, oxatomide, acrivastatin, fexofenadine, ketotifene, loratadine, mizolastine, terfenadine.
  • Antiemetics, antinausea such as: dolasetron, granisetron, ondansetron, tropisetron, proclorperazine.
  • Antipropulsives such as: loperamide.
  • Oral hypoglycemizining antidiabetics such as: metformin, chlorpropamide, glybenclamide, glyclazide, glymepiride, glypizide, glyquidone, glysolamide, pioglitazone, rosiglitazone.
  • Cathartics such as: bisacodil, sodium picosulfate.
  • Anti epileptics such as: valproate, carbamazepine, phenytoin, gabapentin, tiagabine, lamotrigine, topiramate, biperidene, bornaprine, metixene, procyclidine, trihexyphenidyl.
  • Alpha-Blockers such as: doxazosin, terazosin, urapidil.
  • Calcium antagonists such as: nifedipine, nicardipine, diltiazem, verapamil, amlodipine, felodipine.
  • Diuretics such as: chlorthalidone, fenquizone, indapamide, metolazone, xipamide, bumetanide, furosemide, piretanide, toresamide, etozolin.
  • Hypolipemizing agents such as: atorvastatin, fluvastatin, pravastatin, simvastatin, lovastatin.
  • 5HT1 selective antagonists such as: rizatrepan, sumatripan, zolmitripan, pizotifen.
  • Antiparkinson drugs such as: pergolide, carbidopa, levodopa, biperiden.
  • Antidepressant such as: paroxetine, fluvoxamine, fluoxetine, sertraline, mirtazapine.
  • Antibiotics such as: cefadroxil, ofloxacin, ciprofloxacin, doxycyclin, erytromycin, cefaclor, ampicillin, cephradine, doxacillin, cefuroxime axetil, amoxicillin, potassium clavulanate, clarithromicin, norfloxacin.
  • these formulations when contacted with water or aqueous fluids, cause the prompt dispersion, solubilization and/or emulsification of the active ingredient present in the system.
  • Surfactants, cyclodextrins and superdisintegrants present in the amphiphilic structure favor wettability of the system and homogeneous release of the active principles in solution, thus improving gastrointestinal absorption.
  • Example 1 illustrates the invention in greater detail.
  • the resulting capsules have in vitro release not lower than 80% after 30 minutes according to the method described in USP/NF.
  • Example 2 500 g of gelucire 44/14 and 44 g of Solutol HS 15 are melted at a temperature ranging from 55°C to 65°C. The molten mass is added under strong stirring with 2.5 g of Methotrexate to obtain a homogeneous solution/dispersion. The resulting mixture is added in succession under strong stirring with 10 g of sodium sulfosuccinate and 25 g of cross-linked poryvinylpyrroridone (Kollidon® XL).
  • Kollidon® XL cross-linked poryvinylpyrroridone
  • the resulting mixture is left under stirring for at least 15 minutes, at a temperature of at least 55°C; then hard-gelatin capsules, size 0 or double 0, are filled with a distributing syringe, to reach a 550 mg weight for single capsule. Each capsule is then closed and sealed by spraying with 50% ethanol and water and subsequent heating under hot air to obtain the final capsule.
  • the resulting capsules have in vitro release not lower than 75% after 45 minutes according to the method described in USP/NF.
  • gelucire 44/14 510 g of gelucire 44/14 are melted at a temperature ranging from 55°C to 65°C, then added with 5 g of diethylene glycol monoethyl ether (Transcutol®). The molten mass is added under strong stirring with 30 g of Paclitaxel to obtain a homogeneous solution/dispersion. The resulting mixture is added in succession under strong stirring with 5 g of sodium lauryl sulfate and 30 g of beta-cyclodextrins. The resulting mixture is left under stirring for at least 15 minutes, at a temperature of at least 55°C; then hard-gelatin capsules, size 0 or double 0, are filled with a distributing syringe, to reach a 580 mg weight for single capsule.
  • Transcutol® diethylene glycol monoethyl ether
  • Each capsule is then closed and sealed by spraying with 50% ethanol and water and subsequent heating under hot air to obtain the final capsule.
  • the resulting capsules have in vitro release not lower than 75% after 45 minutes in a dissolution bath containing 900 ml of 0.1N hydrochloric acid with rotating paddle at 50 rpm.
  • the final mixture is tabletted to unitary weight of 710 mg/tablet.
  • the resulting tablets were subjected to dissolution test in simulated gastric juices, showing a release of the active ingredient not lower than 75% after 45 minutes.
  • gelucire 50/13 50 g of gelucire 50/13 are melted at a temperature ranging from 60°C to 65°C.
  • the molten mass is added under strong stirring with 25 g of Ketoprofen to obtain a homogeneous dispersion.
  • the resulting mixture is added with 4 of sodium lauryl sulfate under strong stirring.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to prompt-release oral pharmaceutical compositions containing one or more active principles solubilised, suspended or embedded in a suitably formulated amphiphilic matrix for improving in vitro and in vivo bioavailability of medicaments sparingly absorbed through the oral route and/or with problems of high variability of absorption in the gastrointestinal tract.

Description

ORAL PHARMACEUTICAL COMPOSITIONS WITH IMPROVED
BIOAVAILABILITY
ORAL PHARMACEUTICAL COMPOSITIONS WITH IMPROVED BIOAVAILABILITY
The present invention relates to prompt-release oral pharmaceutical compositions containing one or more active principles solubilised, suspended or embedded in an amphiphilic matrix which is suitably formulated to increase in vitro and in vivo the bioavailability of medicaments sparingly absorbed through the oral route and/or with problems of high variability of absorption in the gastrointestinal tract.
Formulation of drugs in amphiphilic matrix systems, with other surfactants, superdisintegrants and other excipients which are used for obtaining pharmaceutical forms having suitable technological properties, allows to increase the in vitro dissolution rate, to improve bioavailability and to have less absorption variability.
The prompt-release compositions of the invention can contain active principles belonging to the therapeutical classes of analgesic, anti- inflammatory, antineoplastic, immunomodulating, antihemetic, antidiabetic, cardiovascular, hypnotic, tranquilizing, antihistamine drugs, antibiotics, antidepressant.
TECHNOLOGICAL BACKGROUND
Prompt-release, fast- absorption and improved bioavailable formulations can be prepared according to different known techniques: Complexes and composites based on cyclodextrins or other polymers, in which the active ingredient has been loaded through solubilisation in water or other organic solvents, co-grinding to dryness or in organic solvents and/or freeze-drying.
Micronisation and amorphisation processes of the active ingredient. Emulsions, microemulsions (W/O, O/W), multiple emulsions ( /O/W). Salification processes, even extemporary, or solubilization of the active ingredient as such or in conventional liquid formulations such as syrups, drops, solutions, soft-gelatin capsules, effervescent forms. Organic solvents and/or cosolvents (such as dioxane, dimethylacetamide, dimethylsulfoxide, dimethyl isosorbide or binary or multiple systems consisting of diethylene glycol monoethyl ether with polyethylene glycols added with non-ionic surfactants.
All the above mentioned procedures suffer, however, from some drawbacks and disadvantages.
Complexes and composites based on cyclodextrins or other polymers require costly processes, which are often difficult to carry out and do not ensure complete complexation of the active ingredient; moreover the active ingredient to polymer ratio is often a limiting factor to the preparation of an easy-to- administer pharmaceutical form.
Micronisation processes do not always ensure significant increases in plasma levels, while increasing the apparent density / volumes and surface areas of the powders thus making the production of capsules, tablets and granulates troublesome. Amorphisation processes, although improving the bioavailability of the drugs, induce recrystallization in the time and often also lower stability of the active ingredient, thus negatively affecting the quality of the medicament.
Emulsions and/or microemulsions, either simple or multiple, are often unstable and cannot carry pharmacologically active amounts of the medicament.
Salification and/or solubilization processes of conventional pharmaceutical forms sometime cannot improve the bioavailability of sparingly permeable and absorbable, or lipophilic, medicaments, due to reprecipitation of the active ingredient in the biological fluids, thus removing the advantage of a technological process aiming at dissolving the medicament in the pharmaceutical formulation. Prompt-release, improved bioavailability formulations should ensure the standardization of the physical pharmaceutical state of the active ingredient, for fast release from the pharmaceutical form and to reduce any deviation from linear release.
DISCLOSURE OF THE INVENTION This object has been attained according to the present invention, through the formulation of an amphiphilic matrix, single or complex, with other surfactants and/or cyclodextrins and/or superdisintegrants.
The compositions of the invention are characterized by a fast onset phase of the amount of drug which under sink conditions remains rapid until complete solubilization, dispersion and/or extemporaneous and/or in situ emulsification of the system, which quickly releases the active ingredient in the gastrointestinal tract.
The prompt-release oral pharmaceutical compositions present invention comprise: 1. a matrix consisting of amphiphilic compounds either liquid or with melting point below 60°C, possibly to form eutectic mixture melting at 35-37°C, in which the active ingredient is at least partially soluble and/or dispersed and/or embedded or granulated with amphiphilic compound previously solubilised or suspended in solvent (preferably water);
2. a surface acting component which is compatible with the amphiphilic matrix and can be homogeneously solubilized and/or dispersed therein;
3. a component based on cyclodextrins and/or superdisintegrants which can be dispersed in the surface-activated amphiphilic matrix or can in turn be loaded on the optionally surface- activated amphiphilic matrix, to obtain a liquid, semisolid or solid form; 4. any other excipients. DETAILED DISCLOSURE OF THE INVENTION
The compositions of the invention can be obtained with a process which comprises the following steps: a) adding surfactants to the amphiphilic matrix, to obtain a homogeneous solution or dispersion; b) solubilizing, suspending, dispersing, totally or partly embedding one or more active principles; c) adding cyclodextrins and/or superdisintegrants, or granulating or dispersing with cyclodextrins and/or polymers; d) optionally adding excipients; e) optionally film-coating with cellulose derivatives or methacrylic acid polymers.
More particularly, according to the present invention:
In step a) the surface-activated amphiphilic matrix is prepared. First any amphiphilic semisolid excipients or mixtures thereof are melted above 60°C, or solubilised or suspended in solvent (preferably water) to obtain a homogeneous solution and/or dispersion, which becomes again semisolid or solid at room temperature, with eutectic properties at temperatures ranging from 35°C to 37°C (body temperature) or able to be used as granulating system. Afterwards, said excipients, which have become liquid upon melting or are already liquid at room temperature, are added with surfactants to obtain a homogeneous dispersion.
In step b), the active ingredient is solubilised, dispersed and/or embedded in the surface-activated amphiphilic matrix from step a) to obtain a homogeneous solution and/or dispersion and/or granules.
In step c), the system from step (b) is added with different amounts of cyclodextrins and/or superdisintegrants until homogeneous dispersion. The resulting system can be distributed into soft- or hard- gelatin capsules to obtain a liquid, semisolid or solid pharmaceutical form inside the capsule. Alternatively, the system from step (b) can be loaded onto cyclodextrins and/or superdisintegrants and/or mixtures thereof to obtain powder, microgranules or granules having good free-flowing and/or tabletting characteristics. In step d), excipients with different functions may be added to transform liquid or semisolid formulations into solid ones for the preparation of capsules, tablets, granulates, microgranules, minitablets, sachets, said excipients being, for example, silica, celluloses, starches, sugars, polyvinyl pyrrolidones, methacrylates, glidants, antiaggregants, lubricants such as magnesium stearate, stearic acid, talc, or the liquid semisolid formulations can be added with other liquid cosolubilizers, such as, water, polyethylene glycols, glycerin, sorbitol.
Other adjuvants can be selected from preservatives (parabens, benzalkonium chloride), mineral and organic acid /bases, antioxidiizers (BHT, BHA, tocopherols), stabilizers (EDTA).
Amphiphilic compounds for use in the present invention comprise polar lipids (lecithin, phosphatidyl choline, phosphatidyl diethanolamine), ceramides, glycol alkyl ethers such as diethylene glycol monoethyl ether
(R)
(Transcutol ), macrogolglycerids consisting of mixtures of mono- di- and triglycerids and polyethylene glycols and fatty acids (gelucire 44/14; gelucire 50/13) mono and diesters, polyethylene glycols hydroxystearates (Solutol® HS 15).
Surfactants for use for use in the present invention comprise phosphatides and lecithins (phosphatidyl cholines, phosphatidyl diethanolamines, sphyngomyelins), anionic and non-ionic emulsifying waxes, sodium lauryl sulfate, sodium dodecyl sulfate, polysorbates, cholic acids, poloxamer, sodium sulfosuccinate, sodium lauryl sarcosinate. Cyclodextrins and superdisintegrants for use in the present invention comprise alpha-beta-gamma cyclodextrins, hydroxyethylcyclodextrins, methylcyclodextrins, hydroxypropylcyclodextrins, sodium starch glycolate (Explotab®), croscarmellose sodium (Acdisol ), cross-linked polyvinylpyrrolidone, Amberlites (IRP 88). According to a general embodiment of the invention, an amphiphilic matrix is first is prepared, which is added with one or more surfactants in amounts that usually do not exceed 10% w/w, preferably in amounts from 0.1% to 5%.
This mixture may be added with amounts of cyclodextrin or superdisintegrant of up to 10%, preferably from 0.1% to 2.5%, to obtain a homogeneous dispersion.
The active ingredient may be dissolved and/or dispersed in this system up to concentrations ranging from 0.1% to 50%, preferably from 0.1% to 4.9%. The resulting formulation may be used for filling into hard- or soft- gelatin capsules.
Alternatively, the liquid or semisolid amphiphilic matrix may be used as granulating component. Once melted, or solubilised/suspended in solvents (preferably water), this matrix containing part of the surfactants, dextrins, superdisintegrants and active ingredient solubilised or dispersed, can be added to a significant amount of superdisintegrants and/or cyclodextrins already containing the remainder of the active ingredient, to obtain a solid composition ready for filling into capsules or sachets, or for transformation into tablets with the addition of suitable adjuvants such as silica, microcrystalline celluloses, starches, lubricants. The semisolid amphiphilic matrix is cooled and subjected to extrusion and/or granulation, to make the formulation compact until obtaining an easy-to-process granule or microgranule. The final pharmaceutical form may be prepared by dry- or wet- granulation.
The capsules, microgranules and/or tablets can be subjected to conventional coating processes with gastro-soluble films or gastro-protected with cellulose and methacrylic polymers.
The active principles which can be conveniently formulated according to the invention comprise:
1. Antineoplastics and immunomodulators, such as: cyclophosphamide, chlorambucil, melfalan, busulfan, methotrexate, fludarabine, mercaptopurine, thioguanine, fluorouracil, tegafur, etoposide, idarubicin, procarbazine, estramustine, hydroxy carbamide, irinotecan, topotecan, tretinoin, medroxyprogesterone, megestrol, tamoxifen, toremifen, bicalutamide, flutamide, aminoglutetimide, anastrozole, exemestane, letrozole, levamisole, cyclosporin, micofenolate mofetil, tacrolimus, doxorubicin, epirubicin, dacarbazine, paclitaxel, daunorubicin, , irinotecan and camptotecins. 2. Detoxicant compounds for cytostatic treatments, such as: calcium folinate, calcium levofolinate, folic acid.
3. Anti-inflammatories, analgesics and antirheumatics, such as: acetaminophen, phenacetin, sodium salicylate, acetametacin, diclofenac, fentiazac, indomethacin, proglumetacin, sulindac, cinnoxicam, meloxicam, piroxicam, tenoxicam, thiaprophenic acid, flurbiprofene, furprofene, ibuprofen, ketoprofen, naproxen, oxaprozin, mefenamic acid, niflumic acid, amtolmetin guacil, nabumetone, nimesulide, etodoloac, celecoxib, glucosamine and its salts. 4. Anti-inflammatories, Anti-ashmatics, such as: olsalazine, 5- aminosalicylic, sulfasalazine, budesonide, ciclesonide,betamethasone, beclomethasone, fhmisolide, triamcinolone, mometasone.
5. Drugs for the treatment of bone diseases, such as: alendronic acid, clodronic acid, etidronic acid, risedronate, tiludronate.
6. Prostatic, such as: tamsulosin.
7. Anti-acne : tretinoin, isotretinoin.
8. Antivirals, such as: acyclovir, amprenavir, saquinavir, ritonavir.
9. Hormons and peptides: growth hormons, insuline, calcitonin, gosereline, leuprolide, buserelin, , follitropin.
10. Ematological, such as : erithropoyetin, bromeline.
11. Antitussives, such as: dextromethorphan, codeine phosphate, levodropropizine.
12. Systemic antihistamines, such as: mequitazine, prometazine, cetrizine, oxatomide, acrivastatin, fexofenadine, ketotifene, loratadine, mizolastine, terfenadine.
13. Antiemetics, antinausea, such as: dolasetron, granisetron, ondansetron, tropisetron, proclorperazine.
14. Antipropulsives, such as: loperamide. 15. Oral hypoglycemizining antidiabetics, such as: metformin, chlorpropamide, glybenclamide, glyclazide, glymepiride, glypizide, glyquidone, glysolamide, pioglitazone, rosiglitazone.
16. Cathartics, such as: bisacodil, sodium picosulfate.
17. Anti epileptics, such as: valproate, carbamazepine, phenytoin, gabapentin, tiagabine, lamotrigine, topiramate, biperidene, bornaprine, metixene, procyclidine, trihexyphenidyl.
18. Alpha-Blockers, such as: doxazosin, terazosin, urapidil. Antihypertensives, ace-inhibitor, betablocker, antiarhitmic and coronarodilators, such as: captopril, labetalol, atenolol, propafenone isosorbide mono- dinitrate, quinapril, enalapril, candesartan ciletexil, amiodarone, valsartan, isradipine.
19. Calcium antagonists, such as: nifedipine, nicardipine, diltiazem, verapamil, amlodipine, felodipine.
20. Diuretics, such as: chlorthalidone, fenquizone, indapamide, metolazone, xipamide, bumetanide, furosemide, piretanide, toresamide, etozolin.
21. Hypolipemizing agents such as: atorvastatin, fluvastatin, pravastatin, simvastatin, lovastatin.
22. 5HT1 selective antagonists such as: rizatrepan, sumatripan, zolmitripan, pizotifen.
23. Antiparkinson drugs, such as: pergolide, carbidopa, levodopa, biperiden. 24. Antidepressant such as: paroxetine, fluvoxamine, fluoxetine, sertraline, mirtazapine. 25. Antibiotics such as: cefadroxil, ofloxacin, ciprofloxacin, doxycyclin, erytromycin, cefaclor, ampicillin, cephradine, doxacillin, cefuroxime axetil, amoxicillin, potassium clavulanate, clarithromicin, norfloxacin. As far as dissolution characteristics are concerned, these formulations, when contacted with water or aqueous fluids, cause the prompt dispersion, solubilization and/or emulsification of the active ingredient present in the system. Surfactants, cyclodextrins and superdisintegrants present in the amphiphilic structure favor wettability of the system and homogeneous release of the active principles in solution, thus improving gastrointestinal absorption.
The following examples illustrate the invention in greater detail. Example 1
500 g of gelucire 44/14 are melted at a temperature ranging from 55°C to 65°C. The molten mass is added under strong stirring with 50 g of Etoposide to obtain a homogeneous solution/dispersion. The resulting mixture is added in succession under strong stirring with 5 g of sodium lauryl sulfate and 45 g of beta-cyclodextrins. The resulting mixture is left under stirring for at least 15 minutes, at a temperature of at least 55°C; then hard-gelatin capsules, size 0 or double 0, are filled with a distributing syringe, to reach a 600 mg weight for single capsule. Each capsule is then closed and sealed by spraying with 50% ethanol and water and subsequent heating under hot air to obtain the final capsule.
The resulting capsules have in vitro release not lower than 80% after 30 minutes according to the method described in USP/NF. Example 2 500 g of gelucire 44/14 and 44 g of Solutol HS 15 are melted at a temperature ranging from 55°C to 65°C. The molten mass is added under strong stirring with 2.5 g of Methotrexate to obtain a homogeneous solution/dispersion. The resulting mixture is added in succession under strong stirring with 10 g of sodium sulfosuccinate and 25 g of cross-linked poryvinylpyrroridone (Kollidon® XL).
The resulting mixture is left under stirring for at least 15 minutes, at a temperature of at least 55°C; then hard-gelatin capsules, size 0 or double 0, are filled with a distributing syringe, to reach a 550 mg weight for single capsule. Each capsule is then closed and sealed by spraying with 50% ethanol and water and subsequent heating under hot air to obtain the final capsule.
The resulting capsules have in vitro release not lower than 75% after 45 minutes according to the method described in USP/NF. Example 3
510 g of gelucire 44/14 are melted at a temperature ranging from 55°C to 65°C, then added with 5 g of diethylene glycol monoethyl ether (Transcutol®). The molten mass is added under strong stirring with 30 g of Paclitaxel to obtain a homogeneous solution/dispersion. The resulting mixture is added in succession under strong stirring with 5 g of sodium lauryl sulfate and 30 g of beta-cyclodextrins. The resulting mixture is left under stirring for at least 15 minutes, at a temperature of at least 55°C; then hard-gelatin capsules, size 0 or double 0, are filled with a distributing syringe, to reach a 580 mg weight for single capsule.
Each capsule is then closed and sealed by spraying with 50% ethanol and water and subsequent heating under hot air to obtain the final capsule.
The resulting capsules have in vitro release not lower than 75% after 45 minutes in a dissolution bath containing 900 ml of 0.1N hydrochloric acid with rotating paddle at 50 rpm.
Example 4
100 g of gelucire 44/14 are melted at a temperature ranging from 55°C and 65°C together with a 5 g of Solutol HS15. The molten mass is added under strong stirring with 50 g of Nimesulide to obtain a homogeneous dispersion. The resulting mixture is added with 4 of sodium dodecylsulfate under strong stirring.
400 g of cross-linked polyvinylpyrrolidone and 50 g of Nimesulide are loaded into a granulator/homogenizer. The mass is mixed for at least 15 minutes. The molten mass prepared above is loaded into the granulator containing polyvinylpyrrolidone and Nimesulide and the components are mixed to obtain a homogeneous granulate. The resulting granules are normalized, then loaded in a mixer, adding in succession 100 g of microcrystalline cellulose, 0.5 g of magnesium stearate and 0.5 g of colloidal silica.
After mixing for 5 minutes, the final mixture is tabletted to unitary weight of 710 mg/tablet. The resulting tablets were subjected to dissolution test in simulated gastric juices, showing a release of the active ingredient not lower than 75% after 45 minutes.
Example 5
50 g of gelucire 50/13 are melted at a temperature ranging from 60°C to 65°C. The molten mass is added under strong stirring with 25 g of Ketoprofen to obtain a homogeneous dispersion. The resulting mixture is added with 4 of sodium lauryl sulfate under strong stirring.
405 g of crosscarmellose sodium (Ac-di-Sol®) and 25 g of Ketoprofen are loaded into a granulator/homogenizer. The mass is mixed for at least 15 minutes. The molten mass prepared above is loaded into the granulator containing Ac-di-Sol® and Ketoprofen and the components are mixed to obtain a homogeneous granulate. The resulting granules are normalized, then loaded in a mixer, adding in succession 125 g of microcrystalline cellulose, 1 g of magnesium stearate and 25 g of colloidal silica. After mixing for 5 minutes, the final mixture is tabletted to unitary weight of 660 mg/tablet. The resulting tablets were subjected to dissolution test in simulated gastric juices, showing a release of the active ingredient not lower than 80% after 45 minutes.
Example 6
500 g of gelucire 44/14 are melted at a temperature ranging from 55°C to 65°C. The molten mass is added under strong stirring with 25 g of Calcium Folinate to obtain a homogeneous solution/dispersion. The resulting mixture is added in succession with 5 g of lecithins and 5 g of beta-cyclodextrins under strong stirring. The resulting mixture is left under stirring for at least 15 minutes, at a temperature of at least 55°C; then hard- gelatin capsules, size 0, are filled with a distributing syringe, to reach a weight of 540 mg for single capsule. Each capsule is then closed and sealed by spraying with 50% ethanol and water and subsequent heating under hot air to obtain the final capsule. The resulting capsules have in vitro release not lower than 80% after 30 minutes.

Claims

1. Oral prompt-release pharmaceutical compositions for the improved oral absorption of active ingredients, comprising: a) a matrix consisting of amphiphilic compounds either liquid or with melting point below 60°C, possibly to form eutectic mixture melting at 35-37°C, in which the active ingredient is at least partially soluble and/or dispersed and/or embedded or granulated with amphiphilic compound previously solubilised or suspended in solvent (preferably water); b) a surface acting component which is compatible with the amphiphilic matrix and can be homogeneously solubilized and/or dispersed therein; c) a component based on cyclodextrins and/or superdisintegrants which can be dispersed in the surface-activated amphiphilic matrix or can in turn be loaded on the optionally surface-activated amphiphilic matrix, to obtain a liquid, semisolid or solid form; d) any other excipients.
2. Compositions as claimed in claim 1 wherein the amphiphilic compounds comprise polar lipids, such as lecithins, phosphatidyl choline, phosphatidyl ethanolamine; ceramides, glycol alkyl ethers such as diethylene glycol monoethyl ether; macrogolglycerids such as mixtures of mono- di- and triglycerids and of mono- and diesters of polyethylene glycols and of fatty acids, polyethylene glycols hydroxystearates.
3. A composition as claimed in claims 1 and/or 2, wherein surfactants comprise phosphatides, phosphatidyl chorines, phosphatidyl diethanolamines, sphyngomyelins, diethanolamines, anionic and non-ionic emulsifying waxes, sodium lauryl sulfate, sodium dodecyl sulfate, polysorbates, cholic acids, poloxamer, sodium sulfosuccinate, sodium lauryl sarcosinate.
4. A composition as claimed in the above claims wherein dextrins comprise alpha-beta- gamma cyclodextrins, hydroxyethylcyclodextrins, methylcyclodextrins, hydroxypropylcyclodextrins.
5. A composition as claimed in the above claims, wherein superdisintegrants comprise sodium starch glycolate, croscarmellose sodium, cross-linked polyvinylpyrrolidone, Amberlites.
6. A composition as claimed in the above claims, wherein the active ingredient is in part present in the amphiphilic matrix and in part loaded on the cyclodextrins and/or superdisintegrants, in the form of minitablets or microgranules.
7. A composition as claimed in any one of the above claims, comprising a gastrosoluble or gastroresistant coating made of cellulose derivatives and/or methacrylic acid polymers.
8. A composition as claimed in any one of the above claims, wherein the active ingredient belongs to therapeutical categories selected from antineoplastics and immunomodulators, detoxicant compounds for cytostatic treatments, anti-inflammatories, analgesics and antirheumatics, drugs for the treatment of bone diseases, antitussives, systemic antihistamines, antiemetics, antinausea agents, antipropulsives, oral hypoglycemizing antidiabetics, cathartics, antiepileptics, alpha-blockers, diuretics, hypolipemizing agents, 5HT1 selective antagonists.
9. Compositions as claimed in claim 8, wherein the active ingredient is selected from etoposide, calcium folinate, methotrexate, procarbazine, fluorouracil, idarubicin, cyclophosphamide, cyclosporin, topotecan, glypizide, glybenclamide, flutamide, nimesulide, piroxicam, ketoprofen.
10. A process for the preparation of the compositions of claims 1 to 9, which comprises the following steps: a) adding surfactants to the amphiphilic matrix, to obtain a homogeneous solution or dispersion; b) solubilizing, suspending, dispersing, totally or partly embedding one or more active principles; c) adding cyclodextrins and/or superdisintegrants, or granulating or dispersing with cyclodextrins and/or polymers; d) optionally adding excipients; e) optionally film-coating with cellulose derivatives or methacrylic acid polymers.
PCT/EP2002/006748 2001-06-26 2002-06-19 Oral pharmaceutical compositions with improved bioavailability WO2003002101A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
DE60205905T DE60205905T2 (en) 2001-06-26 2002-06-19 PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION WITH IMPROVED BIOAVAILABILITY
AU2002321081A AU2002321081B2 (en) 2001-06-26 2002-06-19 Oral pharmaceutical compositions with improved biovailability
AT02754706T ATE303137T1 (en) 2001-06-26 2002-06-19 PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION WITH IMPROVED BIOAVAILABILITY
CA2451377A CA2451377C (en) 2001-06-26 2002-06-19 Oral pharmaceutical compositions with improved bioavailability
EP02754706A EP1401405B1 (en) 2001-06-26 2002-06-19 Oral pharmaceutical compositions with improved bioavailability
JP2003508340A JP4509552B2 (en) 2001-06-26 2002-06-19 Oral pharmaceutical composition with improved bioavailability
US10/482,460 US7867517B2 (en) 2001-06-26 2002-06-19 Oral pharmaceutical composition with improved bioavailability

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI2001A001338 2001-06-26
IT2001MI001338A ITMI20011338A1 (en) 2001-06-26 2001-06-26 ORAL PHARMACEUTICAL COMPOSITIONS WITH IMMEDIATE RELEASE OF THE ACTIVE INGREDIENT

Publications (1)

Publication Number Publication Date
WO2003002101A1 true WO2003002101A1 (en) 2003-01-09

Family

ID=11447931

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/006748 WO2003002101A1 (en) 2001-06-26 2002-06-19 Oral pharmaceutical compositions with improved bioavailability

Country Status (12)

Country Link
US (1) US7867517B2 (en)
EP (1) EP1401405B1 (en)
JP (1) JP4509552B2 (en)
AT (1) ATE303137T1 (en)
AU (1) AU2002321081B2 (en)
CA (1) CA2451377C (en)
DE (1) DE60205905T2 (en)
DK (1) DK1401405T3 (en)
ES (1) ES2247362T3 (en)
IT (1) ITMI20011338A1 (en)
PT (1) PT1401405E (en)
WO (1) WO2003002101A1 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1396268A1 (en) * 2002-09-05 2004-03-10 Bharat Serums & Vaccines Ltd. Stable oxazaphosphorine-2-mercaptoethanesulphonate formulations
JP2008520624A (en) * 2004-11-17 2008-06-19 アレス トレーディング ソシエテ アノニム Benzothiazol formulations and their use
US20080248111A1 (en) * 2005-09-28 2008-10-09 Ethypharm Orodispersible Tablets of Bitter Active Principles
WO2009130394A1 (en) * 2008-04-25 2009-10-29 Pedipharm Oy Gastroresistant cyclosporin formulation
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
US7731989B2 (en) 2001-10-25 2010-06-08 Depomed, Inc. Gastric retained gabapentin dosage form
US8540982B2 (en) 2007-03-22 2013-09-24 Dendreon Corporation Methods for inducing a natural killer (NK) cell-mediated immune response and for increasing NK cell activity
US8592481B2 (en) 2005-12-29 2013-11-26 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10026698A1 (en) 2000-05-30 2001-12-06 Basf Ag Self-emulsifying active ingredient formulation and use of this formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
EP1750717B1 (en) * 2004-02-11 2017-07-19 Rubicon Research Private Limited Controlled release pharmaceutical compositions with improved bioavailability
WO2008100800A1 (en) * 2007-02-09 2008-08-21 Forest Laboratories Holdings Limited Bioavailable formulations of heterocyclic compounds
EP3071182A1 (en) * 2013-11-18 2016-09-28 Sun Pharmaceutical Industries Ltd Oral dispersible composition of a dpp-iv inhibitor
CN106565861A (en) * 2016-11-15 2017-04-19 常熟市凯力达蜂窝包装材料有限公司 Modified cyclodextrin preparation method
US20200232961A1 (en) * 2017-09-19 2020-07-23 The Regents Of The University Of Michigan Characterization and application of polymers for in vivo relevant drug absorption characterization in vitro

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998024430A1 (en) * 1996-12-05 1998-06-11 Sanofi Pharmaceutical compositions containing n-sulphonyl indolin derivatives
US5993858A (en) * 1996-06-14 1999-11-30 Port Systems L.L.C. Method and formulation for increasing the bioavailability of poorly water-soluble drugs
WO2002024172A1 (en) * 2000-09-22 2002-03-28 Galephar M/F Pharmaceutical semi-solid composition of isotretinoin

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8524421D0 (en) * 1985-10-03 1985-11-06 Boots Co Plc Therapeutic agents
GB8630273D0 (en) * 1986-12-18 1987-01-28 Til Medical Ltd Pharmaceutical delivery systems
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
FR2737121B1 (en) * 1995-07-27 1997-10-03 Cl Pharma NEW GALENIC FORMULATIONS OF FENOFIBRATE AND THEIR APPLICATIONS
JPH08283146A (en) * 1995-10-23 1996-10-29 Boehringer Mannheim Gmbh Preparation of molded and compressed prescribing shape of slow release unit and compressed prescribing shape of unit thus obtained
IT1276160B1 (en) * 1995-11-22 1997-10-27 Recordati Chem Pharm READY-RELEASE ORAL PHARMACEUTICAL COMPOSITIONS FOR EXTEMPORARY SUSPENSIONS
FR2742054B1 (en) * 1995-12-06 1998-01-09 Synthelabo PHARMACEUTICAL COMPOSITIONS CONTAINING AN ANTI-INFLAMMATORY AGENT AND VEGETABLE CERAMIDES
DE69811233T2 (en) * 1997-10-27 2003-11-20 Merck Patent Gmbh SOLID SOLUTIONS AND DISPERSIONS OF A POOR WATER-SOLUBLE ACTIVE SUBSTANCE
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5993858A (en) * 1996-06-14 1999-11-30 Port Systems L.L.C. Method and formulation for increasing the bioavailability of poorly water-soluble drugs
WO1998024430A1 (en) * 1996-12-05 1998-06-11 Sanofi Pharmaceutical compositions containing n-sulphonyl indolin derivatives
WO2002024172A1 (en) * 2000-09-22 2002-03-28 Galephar M/F Pharmaceutical semi-solid composition of isotretinoin

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8529955B2 (en) 2001-10-25 2013-09-10 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
US8440232B2 (en) 2001-10-25 2013-05-14 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
US8580303B2 (en) 2001-10-25 2013-11-12 Depomed, Inc. Gastric retained gabapentin dosage form
US8802157B2 (en) 2001-10-25 2014-08-12 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage form
US8475813B2 (en) 2001-10-25 2013-07-02 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
US8192756B2 (en) 2001-10-25 2012-06-05 Depomed, Inc. Gastric retained gabapentin dosage form
US8119166B2 (en) 2001-10-25 2012-02-21 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
US7731989B2 (en) 2001-10-25 2010-06-08 Depomed, Inc. Gastric retained gabapentin dosage form
US8409613B2 (en) 2001-10-25 2013-04-02 Depomed, Inc. Gastric retained gabapentin dosage form
US8231905B2 (en) 2001-10-25 2012-07-31 Depomed, Inc. Gastric retained gabapentin dosage form
US8252332B2 (en) 2001-10-25 2012-08-28 Depomed Inc Gastric retained gabapentin dosage form
US8333992B2 (en) 2001-10-25 2012-12-18 Depomed, Inc. Gastric retained gabapentin dosage form
WO2004022699A2 (en) * 2002-09-05 2004-03-18 Bharat Serums And Vaccines Ltd. Liquid stable composition of oxazaphosphorine with mesna
KR101037313B1 (en) 2002-09-05 2011-05-26 바라트 쎄럼스 앤드 백신스 리미티드 Liquid Stable Composition of Oxazaphosphorine with Mesna
EP1396268A1 (en) * 2002-09-05 2004-03-10 Bharat Serums & Vaccines Ltd. Stable oxazaphosphorine-2-mercaptoethanesulphonate formulations
EA008776B1 (en) * 2002-09-05 2007-08-31 Бхарат Сирумс Энд Вэксинс Лтд. Liquid stable composition of oxazaphosphorine with mesna
WO2004022699A3 (en) * 2002-09-05 2005-03-24 Bharat Serums & Vaccines Ltd Liquid stable composition of oxazaphosphorine with mesna
JP2008520624A (en) * 2004-11-17 2008-06-19 アレス トレーディング ソシエテ アノニム Benzothiazol formulations and their use
US8865219B2 (en) * 2005-09-28 2014-10-21 Ethypharm Orodispersible tablets of bitter active principles
US20080248111A1 (en) * 2005-09-28 2008-10-09 Ethypharm Orodispersible Tablets of Bitter Active Principles
US8592481B2 (en) 2005-12-29 2013-11-26 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
US8540982B2 (en) 2007-03-22 2013-09-24 Dendreon Corporation Methods for inducing a natural killer (NK) cell-mediated immune response and for increasing NK cell activity
WO2009130394A1 (en) * 2008-04-25 2009-10-29 Pedipharm Oy Gastroresistant cyclosporin formulation

Also Published As

Publication number Publication date
EP1401405A1 (en) 2004-03-31
CA2451377C (en) 2011-08-09
ITMI20011338A1 (en) 2002-12-26
DK1401405T3 (en) 2006-01-16
ATE303137T1 (en) 2005-09-15
CA2451377A1 (en) 2003-01-09
JP4509552B2 (en) 2010-07-21
US20040247666A1 (en) 2004-12-09
ITMI20011338A0 (en) 2001-06-26
AU2002321081B2 (en) 2006-11-16
US7867517B2 (en) 2011-01-11
DE60205905T2 (en) 2006-02-16
DE60205905D1 (en) 2005-10-06
EP1401405B1 (en) 2005-08-31
ES2247362T3 (en) 2006-03-01
PT1401405E (en) 2005-11-30
JP2004534832A (en) 2004-11-18

Similar Documents

Publication Publication Date Title
EP1401501B1 (en) Oral pharmaceutical compositions with modified release of the active ingredient
EP1401405B1 (en) Oral pharmaceutical compositions with improved bioavailability
AU2002321081A1 (en) Oral pharmaceutical compositions with improved biovailability
EP2797584B1 (en) Combinations of diacerein and non-steroidal inflammation drugs
CA2715802A1 (en) Pharmaceutical composition for poorly soluble drugs
ES2282062T1 (en) PHARMACEUTICAL COMPOSITION CONTAINING IRBESARTAN.
BRPI0714963A2 (en) process of manufacturing solid dispersions of highly crystalline therapeutic compounds
US4620974A (en) Pharmaceutical composition containing a liquid lubricant
US20090062244A1 (en) Pharmaceutical composition
KR20130100311A (en) Pharmaceutical compositions containing a dgat1 inhibitor
MX2013000015A (en) Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1 '-pyrano[3,4,b]indol]-4-amine.
US4832952A (en) Pharmaceutical composition containing a liquid lubricant
CA2443040A1 (en) Solid pharmaceutical composition comprising 4 -cyano-trifluoro-3-(4-fluorophenyl-sulphonyl) -2-hydroxy-2-methylpropiono- m toluidide and pvp
US20050084526A1 (en) New process 1
CN113365611B (en) Process for preparing pharmaceutical compositions comprising nefopam and acetaminophen and pharmaceutical compositions obtained by the process
AU2002317831B2 (en) Oral pharmaceutical compositions with modified release of the active ingredient
AU2002317831A1 (en) Oral pharmaceutical compositions with modified release of the active ingredient
US4777048A (en) Pharmaceutical composition containing a liquid lubricant
KR20200074759A (en) Solid formulation comprising dutasteride
US20230293514A1 (en) Injectable depot formulation comprising cariprazine free base particles
WO2024043842A1 (en) Pharmaceutical compositions comprising chenodeoxycholic acid (cdca) as active ingredient and other relevant excipients
CA3200729A1 (en) Pharmaceutical composition comprising meloxicam
EP2968154B1 (en) Solid oral dosage formulation of hcv inhibitor in the amorphous state
WO2013100876A1 (en) Risperidone formulations
WO2014195900A2 (en) Oral pharmaceutical compositions for use in dyslipidemias

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2451377

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002321081

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003508340

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002754706

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2004108151

Country of ref document: RU

Kind code of ref document: A

Ref document number: 2004108152

Country of ref document: RU

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2002754706

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10482460

Country of ref document: US

WWG Wipo information: grant in national office

Ref document number: 2002754706

Country of ref document: EP